IQVIA Holdings Inc. $IQV Shares Purchased by Atria Investments Inc

Atria Investments Inc boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 47.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 28,748 shares of the medical research company’s stock after purchasing an additional 9,312 shares during the period. Atria Investments Inc’s holdings in IQVIA were worth $4,530,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in IQV. Pacer Advisors Inc. lifted its position in IQVIA by 5,036.1% in the first quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock worth $153,681,000 after purchasing an additional 854,732 shares during the period. JPMorgan Chase & Co. lifted its position in shares of IQVIA by 45.7% during the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock valued at $448,686,000 after acquiring an additional 798,534 shares during the last quarter. Nordea Investment Management AB lifted its position in shares of IQVIA by 41.7% during the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after acquiring an additional 606,391 shares during the last quarter. Hawk Ridge Capital Management LP acquired a new stake in shares of IQVIA during the 1st quarter valued at $77,096,000. Finally, Nuveen LLC acquired a new stake in shares of IQVIA during the 1st quarter valued at $76,328,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Performance

IQV stock opened at $216.43 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.84 and a current ratio of 0.70. The stock has a market cap of $36.86 billion, a P/E ratio of 29.69, a P/E/G ratio of 2.43 and a beta of 1.32. The firm has a 50 day simple moving average of $197.12 and a 200 day simple moving average of $173.95. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $225.91.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. During the same period last year, the company posted $2.84 earnings per share. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This represents a 12.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the subject of a number of recent research reports. JPMorgan Chase & Co. increased their price objective on IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday. Redburn Partners set a $214.00 price objective on IQVIA in a research report on Wednesday, September 3rd. William Blair reiterated an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Robert W. Baird set a $258.00 price objective on IQVIA and gave the company an “outperform” rating in a research report on Wednesday. Finally, Hsbc Global Res raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $241.41.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.